QCG
AZN icon

Quadrant Capital Group’s AstraZeneca AZN Stock Holding History

Quadrant Capital Group’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.96M Buy
50,521
+1,056
+2% +$204K 0.3% 41
2025
Q4 		$9.09M Buy
49,465
+2,324
+5% +$408K 0.27% 44
2025
Q3 		$7.23M Buy
47,141
+530
+1% +$80.2K 0.24% 53
2025
Q2 		$6.51M Buy
46,611
+698
+2% +$97.8K 0.23% 52
2025
Q1 		$6.75M Buy
45,913
+32,002
+230% +$4.63M 0.25% 46
2024
Q4 		$1.82M Buy
13,911
+126
+0.9% +$17.6K 0.13% 107
2024
Q3 		$2.15M Buy
13,785
+542
+4% +$87.5K 0.15% 93
2024
Q2 		$2.07M Buy
13,243
+1,943
+17% +$292K 0.15% 90
2024
Q1 		$1.53M Sell
11,300
-1,189
-10% -$157K 0.12% 121
2023
Q4 		$1.68M Buy
12,489
+247
+2% +$32.1K 0.14% 104
2023
Q3 		$1.66M Sell
12,242
-73
-0.6% -$9.97K 0.17% 85
2023
Q2 		$1.76M Buy
12,315
+993
+9% +$146K 0.17% 79
2023
Q1 		$1.57M Sell
11,322
-67
-0.6% -$9.01K 0.16% 88
2022
Q4 		$1.54M Buy
11,389
+1,147
+11% +$144K 0.18% 88
2022
Q3 		$1.12M Buy
10,242
+30
+0.3% +$3.81K 0.15% 91
2022
Q2 		$1.35M Buy
10,212
+606
+6% +$79.5K 0.18% 82
2022
Q1 		$1.27M Buy
9,606
+1,148
+14% +$138K 0.15% 88
2021
Q4 		$985K Buy
8,458
+15
+0.2% +$1.76K 0.12% 129
2021
Q3 		$1.01M Buy
8,443
+2,001
+31% +$233K 0.14% 109
2021
Q2 		$772K Buy
6,442
+1,074
+20% +$118K 0.11% 133
2021
Q1 		$534K Buy
5,368
+60
+1% +$6.03K 0.09% 161
2020
Q4 		$531K Sell
5,308
-40
-0.7% -$4.24K 0.1% 141
2020
Q3 		$586K Buy
5,348
+1,038
+24% +$115K 0.13% 115
2020
Q2 		$456K Sell
4,310
-14,108
-77% -$1.46M 0.1% 140
2020
Q1 		$1.65M Buy
18,418
+999
+6% +$94K 0.28% 68
2019
Q4 		$1.71M Buy
17,419
+1,811
+12% +$170K 0.21% 83
2019
Q3 		$1.38M Buy
15,608
+3,267
+26% +$283K 0.21% 79
2019
Q2 		$1M Sell
12,341
-280
-2% -$22K 0.16% 101
2019
Q1 		$1M Buy
12,621
+3,131
+33% +$247K 0.18% 90
2018
Q4 		$706K Buy
9,490
+5,583
+143% +$436K 0.19% 89
2018
Q3 		$294K Buy
3,907
+2
+0.1% +$151 0.08% 165
2018
Q2 		$259K Buy
3,905
+816
+26% +$58.7K 0.09% 186
2018
Q1 		$203K Buy
3,089
+441
+17% +$30.5K 0.07% 234
2017
Q4 		$173K Buy
2,648
+175
+7% +$11.8K 0.07% 250
2017
Q3 		$159K Sell
2,473
-246
-9% -$15.5K 0.07% 267
2017
Q2 		$147K Buy
2,719
+423
+18% +$27.6K 0.07% 257
2017
Q1 		$138K Buy
2,296
+1,403
+157% +$81.7K 0.06% 260
2016
Q4 		$42K Sell
893
-448
-33% -$25.4K 0.02% 493
2016
Q3 		$78K Buy
1,341
+274
+26% +$17.9K 0.05% 302
2016
Q2 		$58K Buy
1,067
+594
+126% +$34.5K 0.04% 358
2016
Q1 		$25K Buy
473
+49
+12% +$2.94K 0.02% 591
2015
Q4 		$27K Buy
424
+275
+185% +$18K 0.02% 491
2015
Q3 		$8K Hold
149
– – 0.01% 718
2015
Q2 		$8K Buy
+149
New +$10.2K 0.01% 742

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Quadrant Capital Group's AZN Position: Q1 2026 in Review

Quadrant Capital Group increased its AstraZeneca (AZN) stake by 2.1% in Q1 2026, buying an estimated $204K and bringing the position to 50,521 shares worth $9.96M. The position accounts for 0.3% of the portfolio, ranked #41.

Quadrant Capital Group first reported a position in AZN in Q2 2015 and has held it in 44 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Quadrant Capital Group held 50,521 shares of AstraZeneca worth $9.96M as of Q1 2026.
  • Quadrant Capital Group bought 1,056 AstraZeneca shares in Q1 2026, an estimated $204K.
  • AstraZeneca made up 0.3% of Quadrant Capital Group's portfolio in Q1 2026, its #41 holding.
  • Quadrant Capital Group first reported a position in AstraZeneca in Q2 2015 and has held it in 44 quarters since.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.